Title : AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

Pub. Date : 2009 Nov 6

PMID : 19878872






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We report design and preclinical evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants. ponatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 Our work supports clinical evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML. ponatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens